ArticleComputational and structural biotechnology journal2026
MUC13-Associated Molecular Interactome in Pancreatic Cancer.
Article in Computational and structural biotechnology journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mucin-13 (MUC13) has emerged as a critical molecular player involved in tumorigenesis, cancer progression, metastasis, and evasion of immune surveillance, including in pancreatic cancer. In this report, we identified MUC13 molecular interactome using an integrated immunoprecipitation and liquid chromatography-mass spectrometry (accession no. of protein data JPST004189) approach combined with systems network biology to determine its plausible functional protein-protein interaction network and associated oncogenic mechanisms. This study reveals a total of 54 key MUC13 interactor proteins (including cyclin-dependent kinase 1, catenin delta 1, Caludin-1, ErbB3-binding protein 1, basic transcription factor 3, tight junction protein 1, etc.). Interestingly, the majority of these interacting proteins is associated with oncogenic and immune checkpoint pathways. These proteins participate in the regulation of programmed cell death protein 1/programmed cell death ligand 1, T cell receptor signaling, and posttranslational protein processing and modifications in the endoplasmic reticulum. In addition, this study suggests that MUC13 may be involved in other cellular processes such as apoptosis, autophagy, senescence, calcium signaling, microRNA activity, lysosomal function, and diabetic cardiomyopathy. Taken together, this study provides the first comprehensive elucidation of the MUC13-associated molecular interactome, which may contribute to pancreatic cancer progression and metastasis. These findings may facilitate the development of new strategies to inhibit pancreatic cancer progression via disrupting MUC13-associated oncogenic molecular network.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.